18F-FDG PET/CT metabolic parameter to predict pathological complete response and survival after neoadjuvant immunotherapy plus chemoradiotherapy in resectable esophageal squamous cell carcinoma
Jichen Yang, Li Ma, Xiaoming Zhao, Peng Jin, Xue Meng, Wenxing Du, Zhe Wu, Wenjie Jiao, Wenfeng Yang · 2026
Read 18F-FDG PET/CT metabolic parameter to predict pathological complete response and survival after neoadjuvant immunotherapy plus chemoradiotherapy in resectable esophageal squamous cell carcinoma by Jichen Yang, Li Ma, Xiaoming Zhao, Peng Jin, Xue Meng, Wenxing Du, Zhe Wu, Wenjie Jiao, Wenfeng Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13584425.txt.
Description
Jichen Yang and co-authors test in 2026 if a sugar based scan can foretell full tumor loss after drug and beam care for throat cancer. The care pairs immune drugs with chemo and beams before surgery. It gives high full loss rates, so a good scan check has real worth.
Twenty one patients with operable disease had scans before care, and most had a repeat scan before surgery. Uptake and bulk traits were logged from each scan. Thirteen patients had full loss of the main tumor. The team checks which scan traits split that group and which track life span after care.
Catalog record
| CREATOR | Jichen Yang, Li Ma, Xiaoming Zhao, Peng Jin, Xue Meng, Wenxing Du, Zhe Wu, Wenjie Jiao, Wenfeng Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |